Allergan (NYSE: AGN) is expected to report Q1 earnings around April 30. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Allergan's revenues will increase 3.6% and EPS will increase 12.8%.

The average estimate for revenue is $1.44 billion. On the bottom line, the average EPS estimate is $0.97.

Revenue details
 Last quarter, Allergan booked revenue of $1.51 billion. GAAP reported sales were 7.6% higher than the prior-year quarter's $1.40 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $1.15. GAAP EPS of $1.06 for Q4 were 18% higher than the prior-year quarter's $0.90 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 87.5%, 50 basis points better than the prior-year quarter. Operating margin was 31.9%, 260 basis points better than the prior-year quarter. Net margin was 21.5%, 150 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $6.15 billion. The average EPS estimate is $4.76.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 415 members out of 440 rating the stock outperform, and 25 members rating it underperform. Among 114 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 111 give Allergan a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Allergan is outperform, with an average price target of $100.81.